II. Indications
-
Intermittent Claudication
- Adjunct while taking other antiplatelet medication (e.g. Aspirin, Clopidogrel)
III. Contraindications
- Congestive Heart Failure (increased mortality)
- Caution in severe hepatic insufficiency
- Caution in GFR <25 ml/min
IV. Mechanism
V. Dosing
- Take 100 mg orally twice daily on an empty Stomach
- Indications for half dose (50 mg orally twice daily)
- Use of strong CYP3A4 Inhibitors (e.g. Itraconazole, Erythromycin)
- Use of strong CYP2C19 Inhibitors (e.g. Omeprazole)
VI. Adverse Effects
- Headache
- Palpitations
-
Left Ventricular Outflow Obstruction
- Increased risk in patients with sigmoid shaped interventricular septum
VII. Safety
- Pregnancy Category C
- Unknown safety in Lactation
VIII. Drug Interactions
- CYP3A4 Inhibitors (e.g. Itraconazole, Erythromycin)
- CYP2C19 Inhibitors (e.g. Omeprazole)
-
Grapefruit juice
- Increases Cilostazol levels
IX. Efficacy
- Full effect may be delayed for 12 weeks
X. Resources
XI. References
- Balinski (2023) Cilostazol, StatPearls, Treasure Island
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
cilostazol (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
CILOSTAZOL 100 MG TABLET | Generic | $0.13 each |
CILOSTAZOL 50 MG TABLET | Generic | $0.11 each |
Ontology: cilostazol (C0055729)
Definition (NCI) | A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C045645 |
SnomedCT | 395239000, 116087001 |
English | 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone, cilostazol, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, cilostazol (medication), CILOSTAZOL, cilostazol [Chemical/Ingredient], Cilostazol (product), Cilostazol (substance), Cilostazol |
Spanish | cilostazol (producto), cilostazol (sustancia), cilostazol |
Ontology: Pletal (C0722654)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C045645 |
English | Pletal, cilostazol (Pletal), pletal, Otsuka brand of cilostazol |